Resumen

REIS SILVEIRA, Anne Michelli; ANTONIO, Marcia Aparecida  y  MIGUEL, Fernanda. In Vitro and in Vivo Therapeutic Equivalence of Rivaroxaban Tablets. Rev. Med [online]. 2023, vol.31, n.1, pp.11-23.  Epub 29-Dic-2023. ISSN 0121-5256.  https://doi.org/10.18359/rmed.6638.

The aim was to analyze the therapeutic equivalence of rivaroxaban tablets through comparative dissolution profiles and a comparative in vivo pharmacokinetic study. Comparative dissolution profiles were conducted for film-coated rivaroxaban tablets of 10, 15, and 20 mg in three media, analyzed by high-performance liquid chromatography. Results were compared using similarity tests (f2). For bioequivalence analysis, an open-label, randomized, crossover clinical trial was conducted, both fasting and postprandial, comparing rivaroxaban 20 mg manufactured by Medley Farmacéutica Ltda. (study drug) with rivaroxaban 20 mg manufactured by Bayer Pharma A/G (Xarelto®, reference drug). Quantification was performed using liquid chromatography coupled with tandem mass spectrometry in MS/MS mode, with rivaroxaban-d4 as the internal standard. In the in vitro dissolution profile analysis, a similarity greater than 50 was determined in all media for rivaroxaban 10, 15, and 20 mg. In the in vivo analysis of the dissolution profile, showed that the Cmáx, ASC0-1, ASC0-inf for the rivaroxaban study were equivalent to the reference and met bioequivalence criteria. Before mentioned demonstrates that, within the physiological pH range, the dissolution kinetics of rivaroxaban 10 mg and 15 mg formulations are similar to the rivaroxaban 20 mg formulation in film-coated tablets. The bioavailability analysis allows for the determination of bioequivalence between the reference and study formulations, inferring a similar pharmacological effect and therapeutic equivalence.

Palabras clave : Rivaroxaban; Liquid Chromatography; Dissolution; Equivalence Study.

        · resumen en Español | Portugués     · texto en Español     · Español ( pdf )